Pharmaceutical

iOnctura expands PI3K inhibitor programme to NSCLC

iOnctura will evaluate roginolisib in combination with GSK’s Jemperli in a Phase II trial.

Jul 10, 2024 - 04:00
iOnctura expands PI3K inhibitor programme to NSCLC
iOnctura will evaluate roginolisib in combination with GSK’s Jemperli in a Phase II trial.
Read the original article

Tags:

Previous Article

Exponentially increasing understanding of early life on Earth

Next Article

iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Alnylam reports growth in sales of rare disease treatments

STAT+: Alnylam reports growth in sales of rare disease ...

Aug 3, 2023

STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

STAT+: An exit interview with Bristol Myers Squibb CEO ...

Oct 30, 2023

FDA expands Pfizer’s RSV vaccine label to include all high-risk adults

FDA expands Pfizer’s RSV vaccine label to include all h...

Oct 24, 2024